The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Related articles in The JI
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dobrzanski, M. J.
Right arrow Articles by Dutton, R. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dobrzanski, M. J.
Right arrow Articles by Dutton, R. W.
The Journal of Immunology, 2004, 172: 1380-1390.
Copyright © 2004 by The American Association of Immunologists

Tc1 and Tc2 Effector Cell Therapy Elicit Long-Term Tumor Immunity by Contrasting Mechanisms That Result in Complementary Endogenous Type 1 Antitumor Responses1

Mark J. Dobrzanski2, Joyce B. Reome, Joseph A. Hollenbaugh and Richard W. Dutton

Trudeau Institute, Saranac Lake, NY 12983

Cytolytic CD8+ effector cells fall into two subpopulations based on cytokine secretion. Type 1 CD8+ T cells (Tc1) secrete IFN-{gamma}, whereas type 2 CD8+ T cells (Tc2) secrete IL-4 and IL-5. Both effector cell subpopulations display predominantly perforin-dependent cytolysis in vitro. Using an OVA-transfected B16 lung metastases model, we show that adoptively transferred OVA-specific Tc1 and Tc2 cells induce considerable suppression, but not cure, of pulmonary metastases. However, long-term tumor immunity prolonged survival times indefinitely and was evident by resistance to lethal tumor rechallenge. At early stages after therapy, protection by Tc2 and Tc1 effector cells were dependent in part on effector cell-derived IL-4, IL-5, and IFN-{gamma}, respectively. Whereas effector cell-derived perforin was not necessary. Over time the numbers of both donor cells diminished to low, yet still detectable, levels. Concomitantly, Tc1 and Tc2 effector cell therapies potentiated endogenous recipient-derived antitumor responses by inducing 1) local T cell-derived chemokines associated with type 1-like immune responses; 2) elevated levels of recipient-derived OVA tetramer-positive CD8 memory T cells that were CD44high, CD122+, and Ly6Chigh that predominantly produced IFN-{gamma} and TNF-{alpha}; and 3) heightened numbers of activated recipient-derived Th1 and Tc1 T cell subpopulations expressing CD25+, CD69+, and CD95+ cell surface activation markers. Moreover, both Tc2 and Tc1 effector cell therapies were dependent in part on recipient-derived IFN-{gamma} and TNF-{alpha} for long-term survival and protection. Collectively, Tc1 and Tc2 effector cell immunotherapy mediate long-term tumor immunity by different mechanisms that subsequently potentiate endogenous recipient-derived type 1 antitumor responses.


Related articles in The JI:

IN THIS ISSUE

The JI 2004 172: 1331-1332. [Full Text]  



This article has been cited by other articles:


Home page
 J. Immunol.Home page
C. S. Umeshappa, H. Huang, Y. Xie, Y. Wei, S. J. Mulligan, Y. Deng, and J. Xiang
CD4+ Th-APC with Acquired Peptide/MHC Class I and II Complexes Stimulate Type 1 Helper CD4+ and Central Memory CD8+ T Cell Responses
J. Immunol., January 1, 2009; 182(1): 193 - 206.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. Sasaki, X. Zhao, A. D. Pardee, R. Ueda, M. Fujita, S. Sehra, M. H. Kaplan, L. P. Kane, H. Okada, and W. J. Storkus
Stat6 Signaling Suppresses VLA-4 Expression by CD8+ T Cells and Limits Their Ability to Infiltrate Tumor Lesions In Vivo
J. Immunol., July 1, 2008; 181(1): 104 - 108.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. de la Luz Garcia-Hernandez, A. Gray, B. Hubby, O. J. Klinger, and W. M. Kast
Prostate Stem Cell Antigen Vaccination Induces a Long-term Protective Immune Response against Prostate Cancer in the Absence of Autoimmunity
Cancer Res., February 1, 2008; 68(3): 861 - 869.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
S.-J. Liu, J.-P. Tsai, C.-R. Shen, Y.-P. Sher, C.-L. Hsieh, Y.-C. Yeh, A.-H. Chou, S.-R. Chang, K.-N. Hsiao, F.-W. Yu, et al.
Induction of a distinct CD8 Tnc17 subset by transforming growth factor-{beta} and interleukin-6
J. Leukoc. Biol., August 1, 2007; 82(2): 354 - 360.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. J. Dobrzanski, J. B. Reome, J. C. Hylind, and K. A. Rewers-Felkins
CD8-Mediated Type 1 Antitumor Responses Selectively Modulate Endogenous Differentiated and Nondifferentiated T Cell Localization, Activation, and Function in Progressive Breast Cancer
J. Immunol., December 1, 2006; 177(11): 8191 - 8201.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
X. S. Liu, J. Dyer, G. R. Leggatt, G. J. P. Fernando, J. Zhong, R. Thomas, and I. H. Frazer
Overcoming Original Antigenic Sin to Generate New CD8 T Cell IFN-{gamma} Responses in an Antigen-Experienced Host.
J. Immunol., September 1, 2006; 177(5): 2873 - 2879.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
D. Xia, S. Hao, and J. Xiang
CD8+ Cytotoxic T-APC Stimulate Central Memory CD8+ T Cell Responses via Acquired Peptide-MHC Class I Complexes and CD80 Costimulation, and IL-2 Secretion.
J. Immunol., September 1, 2006; 177(5): 2976 - 2984.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. N. MacGregor, Q. Li, A. E. Chang, T. M. Braun, D. P.M. Hughes, and K. T. McDonagh
Ex vivo Culture with Interleukin (IL)-12 Improves CD8+ T-Cell Adoptive Immunotherapy for Murine Leukemia Independent of IL-18 or IFN-{gamma} but Requires Perforin.
Cancer Res., May 1, 2006; 66(9): 4913 - 4921.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Nishimura, J. E. Dusak, J. Eguchi, X. Zhu, A. Gambotto, W. J. Storkus, and H. Okada
Adoptive Transfer of Type 1 CTL Mediates Effective Anti-Central Nervous System Tumor Response: Critical Roles of IFN-Inducible Protein-10.
Cancer Res., April 15, 2006; 66(8): 4478 - 4487.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
S. Gandini, A. B. Lowenfels, E. M. Jaffee, T. D. Armstrong, and P. Maisonneuve
Allergies and the Risk of Pancreatic Cancer: A Meta-analysis with Review of Epidemiology and Biological Mechanisms
Cancer Epidemiol. Biomarkers Prev., August 1, 2005; 14(8): 1908 - 1916.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. M. Asemissen, C. Scheibenbogen, A. Letsch, K. Hellstrand, F. Thoren, K. Gehlsen, A. Schmittel, E. Thiel, and U. Keilholz
Addition of Histamine to Interleukin 2 Treatment Augments Type 1 T-Cell Responses in Patients with Melanoma In vivo: Immunologic Results from a Randomized Clinical Trial of Interleukin 2 with or without Histamine (MP 104)
Clin. Cancer Res., January 1, 2005; 11(1): 290 - 297.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. J. Sussman, R. Parihar, K. Winstead, and F. D. Finkelman
Prolonged Culture of Vaccine-Primed Lymphocytes Results in Decreased Antitumor Killing and Change in Cytokine Secretion
Cancer Res., December 15, 2004; 64(24): 9124 - 9130.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. A. Hollenbaugh, J. Reome, M. Dobrzanski, and R. W. Dutton
The Rate of the CD8-Dependent Initial Reduction in Tumor Volume Is Not Limited by Contact-Dependent Perforin, Fas Ligand, or TNF-Mediated Cytolysis
J. Immunol., August 1, 2004; 173(3): 1738 - 1743.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2004 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2004 by The American Association of Immunologists, Inc. All rights reserved.